...Boehringer's Detlev Mennerich told BioCentury that the fund first came across the technology, developed by Sheffield... ...a rodent model of hearing loss. Rivolta is professor of Sensory Stem Cell Biology at Sheffield...
...Branch at Galveston, Galveston, Texas email: sboldogh@utmb.edu CONTACT: Thomas Helleday, Karolinska Institute, Stockholm, Sweden email: t.helleday@sheffield.ac.uk
Sandi...
...lungs and airways. The Helleday Foundation, founded by author Thomas Helleday of the University of Sheffield... ...Phase I trials within two years to treat airway inflammation diseases.
Sandi Wong
Karolinska Institute
The University of Sheffield
8-oxoguanine...
...loss of ambulation. HERCULES is developing the DMD-focused metric in collaboration with The University of Sheffield’s... ...Inc. (NASDAQ:SLDB), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. The University of Sheffield, Sheffield...
...Ltd. (NASDAQ:WVE), which are all developing DMD therapies. Additionally, University of Leicester and University of Sheffield... ...Mass. Business: Musculoskeletal
Mary Romeo
Pfizer Inc.
PTC Therapeutics Inc.
Roche
Sarepta Therapeutics Inc.
Solid Biosciences LLC
Summit Therapeutics plc
The University of Sheffield
University...
...Ltd. (NASDAQ:WVE), which are all developing DMD therapies. Additionally, University of Leicester and University of Sheffield... ...3, 2017) .
Mary Romeo
Pfizer Inc.
PTC Therapeutics Inc.
Roche
Sarepta Therapeutics Inc.
Solid Biosciences LLC
Summit Therapeutics plc
The University of Sheffield
University...
...Boehringer's Detlev Mennerich told BioCentury that the fund first came across the technology, developed by Sheffield... ...a rodent model of hearing loss. Rivolta is professor of Sensory Stem Cell Biology at Sheffield...
...Branch at Galveston, Galveston, Texas email: sboldogh@utmb.edu CONTACT: Thomas Helleday, Karolinska Institute, Stockholm, Sweden email: t.helleday@sheffield.ac.uk
Sandi...
...lungs and airways. The Helleday Foundation, founded by author Thomas Helleday of the University of Sheffield... ...Phase I trials within two years to treat airway inflammation diseases.
Sandi Wong
Karolinska Institute
The University of Sheffield
8-oxoguanine...
...loss of ambulation. HERCULES is developing the DMD-focused metric in collaboration with The University of Sheffield’s... ...Inc. (NASDAQ:SLDB), Cambridge, Mass. Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT), Abingdon, U.K. The University of Sheffield, Sheffield...
...Ltd. (NASDAQ:WVE), which are all developing DMD therapies. Additionally, University of Leicester and University of Sheffield... ...Mass. Business: Musculoskeletal
Mary Romeo
Pfizer Inc.
PTC Therapeutics Inc.
Roche
Sarepta Therapeutics Inc.
Solid Biosciences LLC
Summit Therapeutics plc
The University of Sheffield
University...
...Ltd. (NASDAQ:WVE), which are all developing DMD therapies. Additionally, University of Leicester and University of Sheffield... ...3, 2017) .
Mary Romeo
Pfizer Inc.
PTC Therapeutics Inc.
Roche
Sarepta Therapeutics Inc.
Solid Biosciences LLC
Summit Therapeutics plc
The University of Sheffield
University...